Giovanni Frisullo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3163773/publications.pdf

Version: 2024-02-01

103 papers

2,865 citations

172457 29 h-index 197818 49 g-index

104 all docs

104 docs citations

104 times ranked 4913 citing authors

#	Article	IF	CITATIONS
1	Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after a second ChAdOx1 nCoV-19 dose. Blood, 2022, 139, 2720-2724.	1.4	16
2	Cerebral edema in acute stroke: Effect of thrombolytic treatment. Journal of the Neurological Sciences, 2022, 436, 120206.	0.6	1
3	Autonomic dysfunction in non-critically ill COVID-19 patients during the acute phase of disease: an observational, cross-sectional study. Neurological Sciences, 2022, 43, 4635-4643.	1.9	12
4	Management of Cerebral Venous Thrombosis Due to Adenoviral <scp>COVID</scp> â€19 Vaccination. Annals of Neurology, 2022, 92, 562-573.	5.3	21
5	Autonomic Dysfunction during Acute SARS-CoV-2 Infection: A Systematic Review. Journal of Clinical Medicine, 2022, 11, 3883.	2.4	18
6	Mechanical Thrombectomy for Acute Intracranial Carotid Occlusion with Patent Intracranial Arteries. Clinical Neuroradiology, 2021, 31, 21-29.	1.9	8
7	Effect of the COVID-19 pandemic and the lockdown measures on the local stroke network. Neurological Sciences, 2021, 42, 1237-1245.	1.9	10
8	Mechanical thrombectomy in patients with stroke due to large vessel occlusion in the anterior circulation and low scale score. Journal of Integrative Neuroscience, 2021, 20, 645.	1.7	2
9	Role of Favorable Perfusion Imaging in Predicting the Outcome of Patients with Acute Ischemic Stroke due to Large Vessel Occlusion Undergoing Effective Thrombectomy: A Single-Center Study. Cerebrovascular Diseases Extra, 2021, 11, 1-8.	1.5	2
10	COVID-19 and stroke: from the cases to the causes. Reviews in the Neurosciences, 2021, 32, 659-669.	2.9	6
11	Delirium in acute stroke: A prospective, crossâ€sectional, cohort study. European Journal of Neurology, 2021, 28, 1590-1600.	3.3	19
12	Global impact of COVID-19 on stroke care. International Journal of Stroke, 2021, 16, 573-584.	5.9	104
13	Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia. JAMA Neurology, 2021, 78, 1314.	9.0	89
14	Prospective Observational Study of Safety of Early Treatment with Edoxaban in Patients with Ischemic Stroke and Atrial Fibrillation (SATES Study). Brain Sciences, 2021, 11, 30.	2.3	8
15	Posterior Circulation Endovascular Thrombectomy for Large Vessels Occlusion in Patients Presenting with NIHSS Score â‰뢱0. Life, 2021, 11, 1423.	2.4	9
16	Instrumental Evaluation of COVID-19 Related Dysautonomia in Non-Critically-Ill Patients: An Observational, Cross-Sectional Study. Journal of Clinical Medicine, 2021, 10, 5861.	2.4	14
17	Acute upward gaze palsy: Not always Parinaud syndrome. European Journal of Ophthalmology, 2020, 30, NP5-NP6.	1.3	O
18	A man with sarcoidosis and slurred speech. European Journal of Neurology, 2020, 27, e7-e8.	3.3	1

#	Article	IF	CITATIONS
19	Predicting Factors of Functional Outcome in Patients with Acute Ischemic Stroke Admitted to Neuro-Intensive Care Unit—A Prospective Cohort Study. Brain Sciences, 2020, 10, 911.	2.3	16
20	Stroke and COVID19: Not only a large-vessel disease. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105074.	1.6	13
21	Stroke integrated care pathway during COVID-19 pandemic. Neurological Sciences, 2020, 41, 1673-1675.	1.9	8
22	An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients. Frontiers in Neurology, 2020, 11, 564.	2.4	30
23	Effect of lockdown on the management of ischemic stroke: an Italian experience from a COVID hospital. Neurological Sciences, 2020, 41, 2309-2313.	1.9	39
24	Focal status epilepticus as unique clinical feature of COVID-19: A case report. Seizure: the Journal of the British Epilepsy Association, 2020, 78, 109-112.	2.0	152
25	Nine syndrome. Acta Neurologica Belgica, 2019, 119, 475-476.	1.1	1
26	"Better explanations―in multiple sclerosis diagnostic workup. Neurology, 2019, 92, e2527-e2537.	1.1	44
27	Ischemic stroke: clinical pathway impact. International Journal of Health Care Quality Assurance, 2019, 32, 588-598.	0.9	13
28	Low reliability of anti-KIR4.183–120 peptide auto-antibodies in multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 910-918.	3.0	5
29	Dysphagia and Obstructive Sleep Apnea in Acute, First-Ever, Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 539-546.	1.6	10
30	Ventral Longitudinal Intraspinal Fluid Collection Presenting as Upper Limb Amyotrophy. European Neurology, 2018, 80, 126-127.	1.4	3
31	Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurology, The, 2018, 17, 1053-1060.	10.2	146
32	Response to the letter to the Editor for the manuscript "Sleep and Fatigue in Multiple Sclerosis: A questionnaire-based, cross-sectional, cohort study―by Tomoyuki Kawada. Journal of the Neurological Sciences, 2017, 373, 142.	0.6	0
33	Thrombus in Transit. Neurologist, 2017, 22, 21-23.	0.7	0
34	Sleep and fatigue in multiple sclerosis: A questionnaire-based, cross-sectional, cohort study. Journal of the Neurological Sciences, 2017, 372, 387-392.	0.6	37
35	Post-Encephalitic Parkinsonism and Sleep Disorder Responsive to Immunological Treatment. Clinical EEG and Neuroscience, 2016, 47, 324-329.	1.7	5
36	Thalamic Amnesia Mimicking Transient Global Amnesia. Neurologist, 2015, 19, 149-152.	0.7	5

#	Article	IF	Citations
37	Second-Line Therapy with Fingolimod for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to Natalizumab. European Neurology, 2015, 73, 57-65.	1.4	20
38	Distinct lymphocytes subsets in IgM-related neuropathy: clinical-immunological correlations. Neurological Sciences, 2015, 36, 303-308.	1.9	2
39	Neurofibromatosis Type 1 Associated with Vertebrobasilar Dolichoectasia and Pontine Ischemic Stroke. Journal of Neuroimaging, 2015, 25, 505-506.	2.0	13
40	A Case of Hemiabdominal Myoclonus. Clinical EEG and Neuroscience, 2015, 46, 331-334.	1.7	2
41	Super-Refractory Status Epilepticus. Clinical EEG and Neuroscience, 2015, 46, 335-339.	1.7	5
42	Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study. Multiple Sclerosis Journal, 2014, 20, 1265-1268.	3.0	17
43	From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study. European Neurology, 2014, 71, 233-241.	1.4	4
44	Risk Factor and Etiology Analysis of Ischemic Stroke in Young Adult Patients. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, e221-e227.	1.6	69
45	Sleep disorder associated with antibodies to IgLON5: parasomnia or agrypnia?. Lancet Neurology, The, 2014, 13, 864.	10.2	3
46	Spontaneous sternocleidomastoid muscle hematoma following thrombolysis for acute ischemic stroke. Journal of the Neurological Sciences, 2014, 341, 189-190.	0.6	2
47	Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies. Journal of Neurology, 2013, 260, 2396-2402.	3.6	44
48	Severe Disability in Patients with Relapsing-Remitting Multiple Sclerosis Is Associated with Profound Changes in the Regulation of Leptin Secretion. NeuroImmunoModulation, 2013, 20, 341-347.	1.8	26
49	Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis. Journal of Neuroimmunology, 2013, 265, 124-127.	2.3	27
50	A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. Neurological Sciences, 2013, 34, 197-203.	1.9	3
51	A Prospective Study on 132 Cases of Ocular Palsy. European Neurology, 2013, 70, 10-15.	1.4	6
52	Sleep Modifications in Acute Transient Global Amnesia. Journal of Clinical Sleep Medicine, 2013, 09, 921-927.	2.6	3
53	Tissue-Infiltrating Lymphocytes Analysis Reveals Large Modifications of the Duodenal "Immunological Niche―in Coeliac Disease After Gluten-Free Diet. Clinical and Translational Gastroenterology, 2012, 3, e28.	2.5	25
54	Modulation of LTP at rat hippocampal CA3-CA1 synapses by direct current stimulation. Journal of Neurophysiology, 2012, 107, 1868-1880.	1.8	183

#	Article	IF	Citations
55	Spontaneous recovery from anti-NMDAR encephalitis. Journal of Neurology, 2012, 259, 1964-1966.	3 . 6	14
56	Neurological involvement during legionellosis, look beyond the lung. Journal of Neurology, 2012, 259, 2243-2245.	3 . 6	3
57	Type 1 immune response in progressive multiple sclerosis. Journal of Neuroimmunology, 2012, 249, 112-116.	2.3	13
58	Bilateral thalamic stroke transiently reduces arousals and NREM sleep instability. Journal of the Neurological Sciences, 2011, 300, 151-154.	0.6	33
59	CD4 ⁺ T-bet ⁺ , CD4 ⁺ pSTAT3 ⁺ and CD8 ⁺ T-bet ⁺ T cells accumulate in peripheral blood during NZB treatment. Multiple Sclerosis Journal, 2011, 17, 556-566.	3.0	30
60	Involvement of type I immune responses in swine-origin H1N1 influenza virus infection. Human Immunology, $2011, 72, 632-635$.	2.4	11
61	Circulating CD8+CD56â° perforin+ T cells are increased in multiple sclerosis patients. Journal of Neuroimmunology, 2011, 240-241, 137-141.	2.3	12
62	CD8+ T Cells in Facioscapulohumeral Muscular Dystrophy Patients with Inflammatory Features at Muscle MRI. Journal of Clinical Immunology, 2011, 31, 155-166.	3.8	113
63	Brainstem and spinal cord involvement in a paraneoplastic syndrome associated with anti-Yo antibody and breast cancer. Journal of Neurology, 2011, 258, 921-922.	3.6	7
64	Oculogyric Crisis in a Midbrain Lesion. Archives of Neurology, 2011, 68, 390-1.	4. 5	8
65	Correlations between peripheral blood mononuclear cell production of BDNF, TNFâ€alpha, ILâ€6, ILâ€10 and cognitive performances in multiple sclerosis patients. Journal of Neuroscience Research, 2010, 88, 1106-1112.	2.9	93
66	Demyelinating encephalomyeloradiculitis with Bal \tilde{A}^2 -like lesions. Journal of Neurology, 2010, 257, 1566-1567.	3 . 6	2
67	Multiple sclerosis attacks triggered by hyperprolactinemia. Journal of Neuro-Oncology, 2010, 98, 407-409.	2.9	20
68	Complement-mediated cytotoxicity of antibodies to the GABAB receptor. Lancet Neurology, The, 2010, 9, 343.	10.2	4
69	Epstein-Barr virus antibodies in serum and cerebrospinal fluid from Multiple sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Amyotrophic Lateral Sclerosis. Journal of Neuroimmunology, 2010, 225, 149-152.	2.3	33
70	Acute necrotizing encephalopathy during novel influenza A (H1N1) virus infection. Annals of Neurology, 2010, 68, 111-114.	5. 3	51
71	Vertebral Artery Dissection Presenting With Isolated Occipital Headache. Headache, 2010, 50, 1378-1380.	3.9	4
72	Focal Hyperhidrosis in Tumefactive Multiple Sclerosis. Archives of Neurology, 2010, 67, 1407-8.	4.5	0

#	Article	IF	CITATIONS
73	The Stolen Memory: A Case of Transient Global Amnesia. Biological Psychiatry, 2010, 67, e31-e32.	1.3	1
74	Light chain deposition in peripheral nerve as a cause of mononeuritis multiplex in Waldenström's macroglobulinaemia. Journal of the Neurological Sciences, 2010, 291, 89-91.	0.6	23
75	CD8+Foxp3+ T cells in peripheral blood of relapsing-remitting multiple sclerosis patients. Human Immunology, 2010, 71, 437-441.	2.4	42
76	Pneumonia's link with the head and heart. Lancet, The, 2010, 376, 388.	13.7	4
77	Breastfeeding and Multiple Sclerosis. Archives of Neurology, 2009, 66, 1580.	4.5	10
78	T-bet, pSTAT1 and pSTAT3 expression in peripheral blood mononuclear cells during pregnancy correlates with post-partum activation of multiple sclerosis. Clinical Immunology, 2009, 131, 70-83.	3.2	21
79	Glioblastoma in multiple sclerosis: a case report. Journal of Neuro-Oncology, 2009, 94, 141-144.	2.9	13
80	Regulatory T cells fail to suppress CD4 ^{+â€f} Tâ€bet ⁺ T cells in relapsing multiple sclerosis patients. Immunology, 2009, 127, 418-428.	4.4	78
81	T-bet and pSTAT-1 expression in PBMC from coeliac disease patients: new markers of disease activity. Clinical and Experimental Immunology, 2009, 158, 106-114.	2.6	22
82	pSTAT1, pSTAT3, and Tâ€bet as markers of disease activity in chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the Peripheral Nervous System, 2009, 14, 107-117.	3.1	31
83	Increased CD4+CD25+Foxp3+ T cells in peripheral blood of celiac disease patients: Correlation with dietary treatment. Human Immunology, 2009, 70, 430-435.	2.4	35
84	Motor cortex stimulation for ALS: A double blind placebo-controlled study. Neuroscience Letters, 2009, 464, 18-21.	2.1	33
85	Tourettism in Multiple Sclerosis: A case report. Journal of the Neurological Sciences, 2009, 287, 288-290.	0.6	18
86	The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis. Journal of Neuroimmunology, 2008, 205, 126-134.	2.3	22
87	IL17 and IFNÎ ³ production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. Cytokine, 2008, 44, 22-25.	3.2	53
88	Increased expression of T-bet in circulating B cells from a patient with multiple sclerosis and celiac disease. Human Immunology, 2008, 69, 837-839.	2.4	27
89	Movement disorders in multiple sclerosis: causal or coincidental association?. Multiple Sclerosis Journal, 2008, 14, 1284-1287.	3.0	35
90	A human anti-neuronal autoantibody against GABAB receptor induces experimental autoimmune agrypnia. Experimental Neurology, 2007, 204, 808-818.	4.1	20

#	Article	IF	CITATION
91	Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients. Clinical Immunology, 2007, 124, 284-293.	3.2	25
92	The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing–remitting multiple sclerosis. Journal of Neuroimmunology, 2007, 192, 174-183.	2.3	74
93	Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. Clinical Immunology, 2006, 118, 77-82.	3.2	58
94	Coeliac disease presenting with acute disseminated encephalomyelitis. European Journal of Neurology, 2006, 13, 202-203.	3.3	6
95	pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity. Journal of Neuroscience Research, 2006, 84, 1027-1036.	2.9	129
96	In vivo Effects of Mitoxantrone on the Production of Pro- and Anti-Inflammatory Cytokines by Peripheral Blood Mononuclear Cells of Secondary Progressive Multiple Sclerosis Patients. NeuroImmunoModulation, 2006, 13, 76-81.	1.8	5
97	Neurotrophic Factors and Clinical Recovery in Relapsing-Remitting Multiple Sclerosis. Scandinavian Journal of Immunology, 2005, 62, 176-182.	2.7	77
98	Clinical characteristics, course and prognosis of spinal multiple sclerosis. Spinal Cord, 2005, 43, 731-734.	1.9	22
99	Serum Levels of Anti-Myelin Antibodies in Relapsing-Remitting Multiple Sclerosis Patients during Different Phases of Disease Activity and Immunomodulatory Therapy. Disease Markers, 2005, 21, 49-55.	1.3	23
100	Evidence of involvement of leptin and IL-6 peptides in the action of interferon-beta in secondary progressive multiple sclerosis. Peptides, 2005, 26, 2289-2293.	2.4	17
101	Leptin Enhances the Release of Cytokines by Peripheral Blood Mononuclear Cells from Relapsing Multiple Sclerosis Patients. Journal of Clinical Immunology, 2004, 24, 287-293.	3.8	30
102	Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta. Journal of Neuroimmunology, 2003, 139, 150-154.	2.3	94
103	Relapsing-remitting autoimmune agrypnia. Annals of Neurology, 2001, 50, 668-671.	5. 3	44